TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Non-invasive Ventilation Versus Long-term Oxygen Therapy in COPD Survivors of Acute Hypercapnic Respiratory Failure. A Multicenter Randomized Controlled Trial
Brief Summary: Chronic Obstructive Pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure are more likely to develop exacerbations. Non-invasive ventilation has been proposed to treat acute respiratory failure but little information is available about the benefits of home non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure surviving an acute hypercapnic respiratory failure. The purpose of this study is to determine whether home non-invasive ventilation can reduce recurrent acute hypercapnic respiratory failure in COPD patients who survived an episode of acute hypoxemic respiratory failure (AHRF) treated by Non-invasive ventilation (NIV).


Options:
A: Arm Label: Long Term Oxygen Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non Invasive Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Non Invasive Ventilation | Intervention Type: DEVICE; Name: Non Invasive Ventilation; Assigned to Arm(s): Non Invasive Ventilation
B: Intervention Type: DEVICE; Name: Noninvasive positive pressure ventilation; Assigned to Arm(s): N/A
C: Arm Label: Noninvasive ventilator; Type: EXPERIMENTAL; Interventions: Device: BiPAP mode | Arm Label: LTOT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: BiPAP mode; Assigned to Arm(s): Noninvasive ventilator
D: Arm Label: Active Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) Treatment | Arm Label: Sham/Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP) Treatment; Assigned to Arm(s): Active Treatment | Intervention Type: DEVICE; Name: Sham CPAP device - CPAP device with pressure delivered <1 cm H20; Assigned to Arm(s): Sham/Placebo Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)
Brief Summary: The purpose of this randomized, double blind, placebo-controlled, superiority clinical trial was to assess clinical efficacy of antazoline in rapid conversion of atrial fibrillation during observation sinus rhythm.


Options:
A: Arm Label: Propafenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propafenone | Arm Label: Dronedarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dronedarone | Intervention Type: DRUG; Name: Propafenone; Assigned to Arm(s): Propafenone | Intervention Type: DRUG; Name: Dronedarone; Assigned to Arm(s): Dronedarone
B: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Arm Label: Antazoline; Type: EXPERIMENTAL; Interventions: Drug: antazoline | Intervention Type: DRUG; Name: antazoline; Assigned to Arm(s): Antazoline | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): Placebo
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis
Brief Summary: The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.

The investigational products were used in participants with mild to moderate surgical bleeding during spine, liver, vascular or soft tissue surgery, when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical.


Options:
A: Arm Label: TachoSil®; Type: ACTIVE_COMPARATOR; Interventions: Biological: TachoSil® | Arm Label: Surgicel® Original; Type: ACTIVE_COMPARATOR; Interventions: Device: Surgicel® Original | Intervention Type: BIOLOGICAL; Name: TachoSil®; Assigned to Arm(s): TachoSil® | Intervention Type: DEVICE; Name: Surgicel® Original; Assigned to Arm(s): Surgicel® Original
B: Arm Label: EVARREST® Fibrin Sealant Patch; Type: EXPERIMENTAL; Interventions: Biological: EVARREST® Fibrin Sealant Patch | Arm Label: Standard of Care (SoC); Type: OTHER; Interventions: Other: Standard of Care (SoC) | Intervention Type: BIOLOGICAL; Name: EVARREST® Fibrin Sealant Patch; Assigned to Arm(s): EVARREST® Fibrin Sealant Patch | Intervention Type: OTHER; Name: Standard of Care (SoC); Assigned to Arm(s): Standard of Care (SoC)
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis
Brief Summary: The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.

The investigational products were used in participants with mild to moderate surgical bleeding during spine, liver, vascular or soft tissue surgery, when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical.


Options:
A: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Infrahepatic inferior vena cava clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No infrahepatic inferior vena cava clamping | Intervention Type: PROCEDURE; Name: Infrahepatic inferior vena cava clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: No infrahepatic inferior vena cava clamping; Assigned to Arm(s): B
C: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis
Brief Summary: The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.

The investigational products were used in participants with mild to moderate surgical bleeding during spine, liver, vascular or soft tissue surgery, when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical.


Options:
A: Intervention Type: DRUG; Name: Fibrin sealant (FS2); Assigned to Arm(s): N/A
B: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
C: Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid diluted in 100 ml of saline solution (loading dose), Drug: tranexamic acid undiluted (continous infusion) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tranexamic acid diluted in 100 ml of saline solution (loading dose); Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: tranexamic acid undiluted (continous infusion); Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Human Thrombin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bovine Thrombin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease
Brief Summary: This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, and other similar diseases. The primary hypothesis is that vaccination with V212 vaccine will elicit significant VZV-specific immune responses at approximately 28 days after vaccination 4. The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \>1.0.


Options:
A: Intervention Type: BIOLOGICAL; Name: Measles, Mumps, Rubella and Chickenpox (live vaccine); Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A
C: Arm Label: V212; Type: EXPERIMENTAL; Interventions: Biological: V212 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: V212; Assigned to Arm(s): V212 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 13vPnC vaccine; Type: EXPERIMENTAL; Interventions: Biological: 13 valent pneumococcal conjugate vaccine | Arm Label: 7vPnC vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnc pneumococcal conjugate vaccine | Intervention Type: BIOLOGICAL; Name: 13 valent pneumococcal conjugate vaccine; Assigned to Arm(s): 13vPnC vaccine | Intervention Type: BIOLOGICAL; Name: 7vPnc pneumococcal conjugate vaccine; Assigned to Arm(s): 7vPnC vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Health Partnership Program for Cancer Patients
Brief Summary: The Objectives of this study is

1. To evaluate the efficacy for exercise, diet, and posttraumatic growth as a result of participating in tailored program (Health Partnership Program) for 24 weeks
2. To evaluate the efficacy for quality of life, life satisfaction, health leadership, anxiety, depression, impact of event, social support, cancer belief as a result of participating in tailored program (Health Partnership Program) for 24 weeks
3. To assess the efficacy of such intervention compared with usual care in cancer patients


Options:
A: Arm Label: Experimetal Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored health partnership program | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: Behavioral: Usual care and health education workshop | Intervention Type: BEHAVIORAL; Name: Tailored health partnership program; Assigned to Arm(s): Experimetal Arm | Intervention Type: BEHAVIORAL; Name: Usual care and health education workshop; Assigned to Arm(s): Control Arm
B: Arm Label: Shape-Up following cancer treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shape-Up following cancer treatment | Arm Label: Control intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shape-Up following cancer treatment; Assigned to Arm(s): Shape-Up following cancer treatment
C: Arm Label: Less Intensive Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Less Intensive | Arm Label: Intensive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group | Intervention Type: BEHAVIORAL; Name: Less Intensive; Assigned to Arm(s): Less Intensive Group | Intervention Type: BEHAVIORAL; Name: Intensive Group; Assigned to Arm(s): Intensive Group
D: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral dietary intervention, Other: counseling intervention, Other: educational intervention, Other: preventative dietary intervention, Procedure: quality-of-life assessment | Arm Label: Without Counseling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: quality-of-life assessment | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Lifestyle counseling, Without Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Health Partnership Program for Cancer Patients
Brief Summary: The Objectives of this study is

1. To evaluate the efficacy for exercise, diet, and posttraumatic growth as a result of participating in tailored program (Health Partnership Program) for 24 weeks
2. To evaluate the efficacy for quality of life, life satisfaction, health leadership, anxiety, depression, impact of event, social support, cancer belief as a result of participating in tailored program (Health Partnership Program) for 24 weeks
3. To assess the efficacy of such intervention compared with usual care in cancer patients


Options:
A: Arm Label: Bone marrow transplantation; Type: OTHER; Interventions: Procedure: Bone marrow transplantation | Arm Label: Peripheral blood stem cell transplantation; Type: OTHER; Interventions: Procedure: Peripheral blood stem cell transplantation | Intervention Type: PROCEDURE; Name: Bone marrow transplantation; Assigned to Arm(s): Bone marrow transplantation | Intervention Type: PROCEDURE; Name: Peripheral blood stem cell transplantation; Assigned to Arm(s): Peripheral blood stem cell transplantation
B: Arm Label: Interdisciplinary rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary rehabilitation | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary rehabilitation; Assigned to Arm(s): Interdisciplinary rehabilitation
C: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care
D: Arm Label: Experimetal Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored health partnership program | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: Behavioral: Usual care and health education workshop | Intervention Type: BEHAVIORAL; Name: Tailored health partnership program; Assigned to Arm(s): Experimetal Arm | Intervention Type: BEHAVIORAL; Name: Usual care and health education workshop; Assigned to Arm(s): Control Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy.
Brief Summary: In this clinical trial, the investigators want to know if cabazitaxel is more effective than methotrexate for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in palliative treatment.


Options:
A: Arm Label: Cabazitaxel; Type: EXPERIMENTAL; Interventions: Drug: Cabazitaxel | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Cabazitaxel; Assigned to Arm(s): Cabazitaxel | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate
B: Arm Label: cetuximab plus radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: cetuximab | Arm Label: cisplatin plus radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin (associated to radiotherapy) | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): cetuximab plus radiotherapy | Intervention Type: DRUG; Name: cisplatin (associated to radiotherapy); Assigned to Arm(s): cisplatin plus radiotherapy
C: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A
D: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ALFApump® System Versus Large Volume Paracentesis in the Treatment of Refractory Ascites. A Multicentre Randomised Controlled Study.
Brief Summary: This is a multicentre, open, randomised, and controlled trial conducted in sixty (60) patients diagnosed with refractory or recurrent ascites. Patients will be randomised (enrolled) to either treatment arm A- implanted with the ALFApump System or treatment arm B-standard of care with evacuation large volume paracentesis. The main aims of the study are to determine the paracentesis free survival, defined as the time to the first large volume therapeutic paracentesis \> 5 litres. The secondary aims are to assess non-inferiority of cirrhosis-related complications in the group of patients randomized to the ALFApump system group, as well as nutritional effects, resource utilisation, patient quality of life and survival non-inferiority.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: TIPS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paracenthese | Intervention Type: PROCEDURE; Name: TIPS; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Paracenthese; Assigned to Arm(s): 2
B: Arm Label: Standard medical treatment plus albumin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diuretics plus human albumin | Arm Label: Standard medical treatment; Type: OTHER; Interventions: Drug: Diuretics (standard medical treatment) | Intervention Type: DRUG; Name: Diuretics plus human albumin; Assigned to Arm(s): Standard medical treatment plus albumin | Intervention Type: DRUG; Name: Diuretics (standard medical treatment); Assigned to Arm(s): Standard medical treatment
C: Arm Label: Albumin plus midodrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: albumin, Drug: Midodrine | Arm Label: salin solution plus pills; Type: PLACEBO_COMPARATOR; Interventions: Drug: albumin, Drug: Placebo | Intervention Type: DRUG; Name: albumin; Assigned to Arm(s): Albumin plus midodrine, salin solution plus pills | Intervention Type: DRUG; Name: Midodrine; Assigned to Arm(s): Albumin plus midodrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): salin solution plus pills
D: Arm Label: ALFApump removal of ascites; Type: EXPERIMENTAL; Interventions: Device: ALFApump removal of ascites | Arm Label: Large volume paracentesis for removal of ascites; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Large volume paracentesis for removal of ascites | Intervention Type: DEVICE; Name: ALFApump removal of ascites; Assigned to Arm(s): ALFApump removal of ascites | Intervention Type: PROCEDURE; Name: Large volume paracentesis for removal of ascites; Assigned to Arm(s): Large volume paracentesis for removal of ascites

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Sham Controlled Randomised Trial of Intraperitoneal Bupivacaine During Acute Laparoscopic Cholecystectomy
Brief Summary: Laparoscopic cholecystectomy (removal of the gall bladder via 'keyhole surgery') is a common procedure. This can be performed as an emergency operation when a patient has a complication of gall stones such as acute inflammation or pancreatitis. There are several trials which demonstrate that placing local anaesthetic inside the abdomen at the site of gall bladder surgery during a planned elective operation decreases post operative pain. This is the first trial to investigate the efficacy of this local anaesthetic during emergency cholecystectomy.


Options:
A: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: 0.9% normal saline solution | Arm Label: Subperitoneal injection; Type: EXPERIMENTAL; Interventions: Drug: Bupivocaine | Arm Label: Topical LA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivocaine | Intervention Type: DRUG; Name: Bupivocaine; Assigned to Arm(s): Subperitoneal injection, Topical LA | Intervention Type: DRUG; Name: 0.9% normal saline solution; Assigned to Arm(s): Control
B: Arm Label: Saline sham injection; Type: SHAM_COMPARATOR; Interventions: Other: Normal saline | Arm Label: Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Bupivacaine | Intervention Type: OTHER; Name: Normal saline; Assigned to Arm(s): Saline sham injection
C: Arm Label: standard anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: standard anesthesia with ropivacaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): standard anesthesia with ropivacaine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: videolaparocholecystectomy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: videolaparocholecystectomy | Arm Label: 3; Type: NO_INTERVENTION; Interventions: Procedure: videolaparocholecystectomy | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 1, 2 | Intervention Type: PROCEDURE; Name: videolaparocholecystectomy; Assigned to Arm(s): 3

Answer: B